Cloning Resources
  Recent News |  Tags |  Organ & Tissue Cloning |  Animal Cloning |  Definitions |  Archives |  About |  Newsletter |  Subscribe to CloningResources.com RSS Fee Subscribe
New Articles
Gene therapy prevents blindness in an animal model of mitochondrial dysfunction 9/8/2008

New stem cell tools to aid drug development 9/7/2008

Updated Guidelines For Stem Cell Research Released 9/7/2008

USC Breaks Ground on Stem Cell Center 9/6/2008

Cardiac cell transplant studies show promise in cardiac tissue repair 9/5/2008

Scientists reveal changes to embryonic stem cells caused by Down syndrome 9/5/2008

Hearing restoration may be possible with cochlear repair after transplant of human cord blood cells 9/4/2008

Stem cell transplantation benefits mice with childhood motor neuron disease 9/3/2008

Blood vessel cells are instructed to form tube-like structures 8/31/2008

Engineers Create Bone that Blends into Tendons 8/30/2008

Researchers Devise Means To Create Blood By Identifying Earliest Stem Cells 8/29/2008

Stem cells stand up for themselves 8/26/2008

$3.2 Million for Rutgers to Apply New Mix of Biology, Engineering, Physical Sciences toward Stem Cell Breakthroughs 8/25/2008

Bone marrow stem cells may help control inflammatory bowel disease 8/22/2008

Limbs saved by menstrual blood stem cells 8/21/2008

Gene Variant Increases Risk Of Blindness (7/24/2007)

Tags:
amd, eyes

Researchers have found a gene variant that can more than double the risk of developing the degenerative eye disease, age-related macular degeneration.

The macula lies at the centre of the retina and is essential for detailed central vision. Degeneration of the macula interferes with important tasks such as reading and driving.

Age-related macular degeneration (AMD), the cause of which is poorly understood, is the leading cause of visual loss in older people and the commonest cause of blindness in the USA and European countries.

The researchers based their findings on studies of patients with AMD (603 from England and 244 from Scotland) who were compared with 701 unaffected people.

They found that a variant in the complement C3 gene influenced the risk of developing AMD. For the 30% of the population who carry one copy of the so-called 'fast' variant the risk of AMD was increased by 70%, and for the 4% of people with two copies of the 'fast' variant the risk of AMD was more than doubled.

AMD can take two forms called 'wet' (also called choroidal neovascularisation or CNV) and 'dry' (also called geographic atrophy or GA). The 'fast' variant in the C3 gene increases the risk of both forms of the disease.

The complement C3 gene has a central role in the immune system. The results of this research provide strong evidence that inflammation is an important part of the disease process in AMD.

The goal of this type of research is to achieve a full understanding of the causes of AMD, which should lead to the development of better treatment and strategies for prevention of this common and debilitating disease.

Professor John Yates, at the University of Cambridge, said: "AMD is devastating for those who lose their site and we hope that a better understanding of what causes the disease will eventually lead to better treatment and perhaps prevention".

The initial studies were carried out by a team of researchers led by Professor Yates and Professor Tony Moore at the UCL Institute of Ophthalmology. Further work to confirm the initial findings was carried out by researchers in Scotland led by Professor Alan Wright, Medical Research Council Human Genetics Unit, Edinburgh.

This research, reported in the New England Journal of Medicine, has been funded by the Medical Research Council.

Note: This story has been adapted from a news release issued by University of Cambridge

Vegas Hotel - Loans - Credit Card Consolidation - Best Credit Cards

Post Comments:

Search

  Archives |  Submit News |  Advertise With Us |  Contact Us |  Links
All contents © 2000 - 2009 Web Doodle, LLC. All rights reserved.
Web Doodle, LLC does not provide medical advice, diagnosis or treatment. Please read our disclaimer